03/22/23 2:00 AMNasdaq : MRNA managementBenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello DamianiBenevolentAI, a leading, clinical-stage AI-enabled drug discovery and development company, today announces the appointment of Marcello Damiani to its Board of Directors. Drawing from his senior executive leadership experience at global organisations such as Moderna and bioMérieux, Marcello offers a unique perspective and understanding of...RHEA-AIneutral
03/14/23 5:40 PMNasdaq : MRNA clinical trialModerna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual MeetingModerna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentationRHEA-AIneutral
03/10/23 11:00 AMNasdaq : MRNA Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023Expansion includes new West Coast offices in South San Francisco, California and Seattle, Washington New offices complement existing locations in Cambridge, MA; Norwood, MA; Atlanta, GA; Bethesda, MD; and Princeton, NJ Moderna currently has offices in 17 locations worldwide Company plans to hireRHEA-AIvery positive
02/28/23 7:30 AMNasdaq : MRNA conferencesModerna to Present at Cowen's 43rd Annual Health Care ConferenceModerna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6 th at 9:10 a.m. ET.RHEA-AIneutral
02/23/23 7:00 AMNasdaq : MRNA earningsModerna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business UpdatesFourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12 Company reiterating approximately $5 billion in COVID-19 sales contracted for deliveryRHEA-AIpositive
02/22/23 4:05 PMNasdaq, NYSE : MRNA, MRK Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete ResectionModerna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSDRHEA-AIvery positive
02/22/23 7:00 AMNasdaq : MRNA Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing TherapiesCollaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseases Life Edit toRHEA-AIpositive
02/17/23 11:00 AMNasdaq : MRNA covid-19Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4/5)) are currently authorized for use in individuals 18 years of age and older inRHEA-AIneutral
02/16/23 4:05 PMNasdaq : MRNA clinical trialModerna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine CandidatemRNA-1010 demonstrated superiority on seroconversion rates for A/H3N2 and A/H1N1, superiority on geometric mean titer ratios for A/H3N2, and non-inferiority on geometric mean titer ratios for A/H1N1 Non-inferiority was not met for seroconversion rates and geometric mean titer ratios for theRHEA-AIneutral
02/03/23 8:45 AMNasdaq : PSNL, MRNA clinical trialPersonalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical TrialsPersonalis, Inc., a leader in advanced genomics for precision oncology, and Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform ® as part of upcoming clinical studies evaluating mRNA-4157/V940, an...RHEA-AIneutral